Antibody-based immunological therapies

Current Opinion in Immunology

Volumn 9, Issue 5, 1997, Pages 717-722

  Scott, Andrew M ^a   Welt, Sydney ^b  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY;

BREAST CANCER; CANCER IMMUNOTHERAPY; COLON CANCER; IMMUNOTHERAPY; LYMPHOMA; REVIEW;

EID: 0030659504     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(97)80054-4     Document Type: Article

References (48)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
2. Old LJ. Immunotherapy for cancer. of outstanding interest Sci Am. 1996;136-143 An excellent overview of the historical development and current status of immunotherapy for cancer.
3. Scott AM, Cebon JS. Clinical promise of tumor immunology. of special interest Lancet. 349:1997;19-22 This review summarises the current status of monoclonal antibody and vaccine based approaches for the immunotherapy of cancer.
4. 131I-B1 (anti-CD20) antibody phase I therapy trial in non-Hodgkin's lymphoma. The results (a high response rate, long duration of responses) indicate the efficacy of this therapy in patients with refractory B cell lymphoma.
5. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 346:1995;336-340.
6. Knox SJ, Goris ML, Trisler K, Negrin R, Davis T, Liles T-M, Grillo-Lopez A, Chinn P, Varns C, Ning S-C, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoms. Clin Cancer Res. 2:1996;457-470.
7. Juweid M, Sharkey RM, Markovitz A, Behr T, Swayne LC, Dunn R, Hansen HJ, Shevitz J, Leung S-O, Rubin AD, et al. Treatment of non-Hodgkin's lymphoma with radiolabelled murine, chimeric, or humanised LL2, an anti-CD22 monoclonal antibody. Cancer Res. 55:1995;5899S-5907S. (suppl).
8. White CA, Halpern SE, Parker BA, Miller RA, Hupf HB, Shawler DL, Collins HA, Royston I. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood. 87:1996;3640-3649.
9. Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, Figg WD, Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood. 88:1996;1188-1197.
10. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, et al. A phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 83:1994;1760-1768.
11. Jurcic JG, Caron PC, Miller WH Jr, Yao TJ, Maslak P, Finn RD, Larson SM, Warrell RP Jr, Scheinberg DA. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia. 9:1995;244-248.
12. Jurcic JG, Caron PC, Nikula TK, Papadopolous EB, Finn RD, Gansow OA, Miller WH Jr, Geerlings MW, Warrell RP Jr, Larson SM, Scheinberg DA. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 55:1995;5908S-5910S. (suppl).
13. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 85:1995;1122-1131.
14. Österberg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol. 15:1997;1567-1574.
15. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, Brechbiel MW, Jaffe ES, Fleisher TA, Goldman CK, et al. Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 86:1995;4063-4075.
16. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayer R, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Duke's C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 343:1994;1177-1183.
17. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci USA. 76:1979;1438-1442.
18. Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res. 40:1980;717-720.
19. Fagerberg J, Hjelm A-L, Ragnhammar P, Frödin J-E, Wizgell H, Mellstedt H. Tumour regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res. 55:1995;1824-1827.
20. Fagerberg J, Ragnhammar P, Liljefors M, Hjelm A-L, Mellstedt H, Frödin J-E. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol Immunother. 42:1996;81-87.
21. Goldenberg DM. Cancer Therapy with Radiolabelled monoclonal antibodies. 1995;CRC Press, Boca Raton, Florida.
22. 131I-CC49 mAb, directed against the TAG-72 antigen. Despite stem-cell support, no responses were seen, indicating the need for repeated infusions of radiolabelled antibodies with humanised constructs if efficacy is to be achieved.
23. 131Iodine-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol. 12:1994;1561-1571.
24. 125I to a metastatic colon cancer using the murine mAb A33. Internalisation of the antigen - mAb complex resulted in the retention of radioactivity for over one month in patients. Tumor responses observed suggest that mAb trafficking to the region of the tumor cell nucleus is possible in vivo with this antigen system.
25. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu G-F, Whitehead RH, Groenen L, Scott AM, et al. The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Nat Acad Sci USA. 94:1997;469-474.
26. Daghighian F, Barenswaard E, Welt S, Humm J, Scott AM, Willingham MC, McGuffie E, Old LJ. Enhancement of radiation dose to the nucleus due to the transport of I-125 labeled A33 monoclonal antibody across the cytosol by vesicular internalisation. J Nuc Med. 37:1996;1052-1057.
27. y antibody (B3) chemically linked to a genetically engineered Pseudomonas exotoxin PE38 was studied in patients with advanced tumors. This is the first study with immunotoxins to demonstrate anti-tumor activity in solid tumors.
28. Holliger P, Prospero T, Winter G. Diabodies: small bivalent and bispecific antibody fragments. Biophysics. 90:1993;6444-6448.
29. Hu S-Z, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JYC, Shively JE, Wu AM. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56:1996;3055-3061.
30. Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. 15:1997;159-163.
31. Jakobovits A, Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, Abderrahim H, Noguchi M, Smith DH, et al. Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs. Ann NY Acad Sci. 764:1995;525-535.
32. Begent RHJ, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, Hope-Stone LD, Cushen N, Keep PA, Johnson CJ, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat Med. 2:1996;979-984.
33. 111Indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose. Cancer Res. 56:1996;5179-5185.
34. HER2 receptor in patients with malignancy, and it has implications for a range of potential new cancer therapies based on altered growth factor receptor expression in tumors.
35. Pegram M, Lipton A, Pietras R, Hayes D, Weber B, Baselga J, Tripathy D, Twadell T, Glaspy J, Slamon D. Phase II study of intravenous recombinant humanised anti-p185 HER-2/neu monoclonal antibody (rHu Mab HER-2) plus cisplatinum in patients with HER2/neu overexpressing metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol. 14:1995;106a.
36. y) antibodies generated against synthetic and natural Le(y) determinants. Proc Nat Acad Sci USA. 91:1995;12957-12961.
37. 131I-labeled chimeric monoclonal antibody G250. J Clin Oncol. 15:1997;1529-1537.
38. Divgi CR, Bander NH, Welt S, Scott AM, Gulec S, Motzer R, Finn RD, Oosterwijk E, Williams J, Broussard E, et al. Phase I/II trial with I-131 labeled monoclonal antibody G250 in metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol. 14:1995;423.
39. Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother. 19:1996;184-191.
40. Murray JL, Kleinerman ES, Jia SF, Rosenblum MG, Eton O, Buzaid A, Legha S, Ross MI, Thompson L, Mujoo K, et al. Phase la/lb trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother Emphasis Tumor Immunol. 19:1996;206-217.
41. Minasian LM, Yao TJ, Steffens TA, Scheinberg DA, Williams L, Riedel E, Houghton AN, Chapman PB. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer. 75:1995;2251-2257.
42. Luiten RM, Coney LR, Fleuren GJ, Warnaar SO, Litvinov SV. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer. 74:1996;735-744.
43. Tibbens JG, Boerman OC, Massauger LFAG, Schilf CPT, Claessens RAMJ, Corstens FHM. Pharmacokinetics, biodistribution and biologic effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients. Int J Cancer. 66:1996;477-483.
44. Renner C, Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev. 145:1995;179-209.
45. Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erB-2 and FcγRIII. J Hematother. 4:1995;453-456.
46. Canevari S, Stoter G, Arienti F, Boils G, Colnaghi MI, Di Re EM, Eggermont AMM, Hoo Goey S, Gratama JW, Lamers CHJ, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Can Inst. 87:1995;1463-1469.
47. Baselga J, Mendelsohn J. The epidermal growth factor as a target for therapy in breast carcinoma. Breast Cancer Res Treat. 29:1994;127-138.
48. Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, Cohen A, Larson SM, Old LJ, Rettig WJ. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 12:1994;1193-1203.